Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents

Details for Australian Patent Application No. 2006235490

Owner Details removed by request.

Inventors Details removed by request.

Agent Details removed by request.

Pub. Number AU-A-2006235490

PCT Pub. Number WO2006/110814

Priority 60/670,226 12.04.05 US

Filing date 12 April 2006

Wipo publication date 19 October 2006

International Classifications

A61K 31/426 (2006.01) - 1,3-Thiazoles

A61K 31/167 (2006.01) - having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 31/04 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 31/12 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 33/00 (2006.01) Antiparasitic agents

A61P 33/02 (2006.01) Antiparasitic agents

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

6 December 2007 PCT application entered the National Phase

10 November 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006235492-1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors

2006235489-Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases